US drug maker Pfizer is expected to formally drop its third takeover bid, worth £69bn, for UK-based drug manufacturer AstraZeneca after the final deadline officially expired at 5pm yesterday.
Under UK acquisition rules, both companies should have a three-month cooling-off period before resuming negotiations if AstraZeneca begins the discussion, otherwise Pfizer can make a new bid in six months.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The three-month cooling-off period is expected to give both firms the time to decide their next respective move.
Pfizer has been working for months to reach a deal with AstraZeneca, despite continued rejections from the UK drug maker.
On 19 May, AstraZeneca board had clearly rejected an improved ‘final’ takeover offer of £69bn from Pfizer.
Under the terms of the improved proposal, AstraZeneca shareholders would receive £24.76 in cash and 1.747 shares in the combined company, worth a combined £55 for each share they currently hold.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe improved proposal makes a substantial increase of about 15% over the current value of Pfizer’s 2 May proposal of £62.6bn.
Pfizer said that the improved proposal of £55 per share is final and will not be raised as it increased the ratio of cash AstraZeneca shareholders would receive, from 33% to 45%.
Earlier this month, the takeover bid raised concerns regarding the company’s commitment to research and development, as well as potential job losses in UK drug research.
Image: Pfizer world headquarters in New York City, US. Photo: courtesy of Jim.henderson.
